Dr. Tracy T. Tang has over 20 years of experience in cancer research. Currently, she is Vice President, Head of Biology at Vivace Therapeutics, an oncology-focused small molecule drug discovery and development company targeting the Hippo-YAP/TEAD pathway. Prior to joining Vivace in 2015, she gained extensive experience in translational medicine at OncoMed Pharmaceuticals, leading and managing many aspects of the clinical biomarker discovery and operations for the company's anti-NOTCH and anti-WNT clinical trials. Dr. Tang began her career at Genentech, where she managed several large-scale research projects, including the company's Cancer Genome Project, and was a major contributor to the development of the Hedgehog pathway inhibitor GDC-0449 (Vismodegib), which gained FDA approval in 2012. She earned a doctoral degree in biology from the Massachusetts Institute of Technology and holds a bachelor’s degree in Molecular and Cell Biology, with emphasis in Biochemistry, from the University of California, Berkeley.
